Brainstorm announces completion of all dosing in nurown® phase 2 ms study

New york, dec. 18, 2020 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing phase 2 trial evaluating nurown® (msc-ntf cells) as...
BCLI Ratings Summary
BCLI Quant Ranking